OncoDaily IO· @OncoDailyIO · X·· 20 小时前评分70
正文 · 原文
🧬 EMERALD-3 exploratory analysis in HCC:
Mean liver function scores remained stable during treatment with STRIDE ± lenvatinib + TACE.
Survival estimates generally favored the combinations, but a definitive OS benefit remains unproven.
https://oncodaily.com/oncolibrary/immune-oncology/emerald-3-trial-esmo
#ESMO2026 #OncoDaily #EMERALD3
14 浏览 · 1 赞 · 0 转发 · 0 回复
来源：OncoDaily IO · x.com